[1]
|
Sung, H., Ferlay, J., Siegel, R.L., et al. (2021) Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA: A Cancer Journal for Clinicians, 71, 209-249.
https://doi.org/10.3322/caac.21660
|
[2]
|
Schweitzer, A., Horn, J., Mikolajczyk, R.T., Krause, G. and Ott, J.J. (2015) Estimations of Worldwide Prevalence of Chronic Hepatitis B Virus Infection: A Systematic Review of Data Published between 1965 and 2013. Lancet, 386, 1546-1555. https://doi.org/10.1016/S0140-6736(15)61412-X
|
[3]
|
Zhou, M., Wang, H., Zeng, X., et al. (2019) Mortality, Morbidity, and Risk Factors in China and Its Provinces, 1990- 2017: A Systematic Analysis for the Global Burden of Disease Study 2017. Lancet, 394, 1145-1158.
https://doi.org/10.1016/S0140-6736(19)30427-1
|
[4]
|
Kusano, H., Akiba, J., Ogasawara, S., et al. (2013) Pegylated Interferon-α2a Inhibits Proliferation of Human Liver Cancer Cells in vitro and in vivo. PLoS One, 8, e83195. https://doi.org/10.1371/journal.pone.0083195
|
[5]
|
Luo, X., Yu, J.-X., Xie, L., Ma, W.-J. and Wang, L.-H. (2017) Clinical Analysis of Polyethylene Glycol Interferon-α Treatment in 155 Hepatitis B e Antigen (HBeAg)-Positive Chronic Hepatitis B (CHB) Patients. Annals of Hepatology, 16, 888-892. https://doi.org/10.5604/01.3001.0010.5279
|
[6]
|
Kumar, A., Taghi Khani, A. and Swaminathan, S. (2021) Type I Interferons: One Stone to Concurrently Kill Two Birds, Viral Infections and Cancers. Current Research in Virological Science, 2, Article ID: 100014.
https://doi.org/10.1016/j.crviro.2021.100014
|
[7]
|
张秀翠, 蒲蕊, 吴婷, 等. 核苷(酸)类似物及干扰素治疗对慢性HBV感染者远期肝癌和死亡风险的影响[J]. 肝脏, 2017, 22(4): 305-309.
|
[8]
|
Mao, Q.-G., Liang, H.-Q., Yin, Y.-L., et al. (2022) Comparison of Interferon-α-Based Therapy and Nucleos(t)ide Analogs in Preventing Adverse Out-comes in Patients with Chronic Hepatitis B. Clinics and Research in Hepatology and Gastroenterology, 46, Article ID: 101758. https://doi.org/10.1016/j.clinre.2021.101758
|
[9]
|
Li, S.-Y., Li, H., Xiong, Y.-L., et al. (2017) Peginter-feron Is Preferable to Entecavir for Prevention of Unfavourable Events in Patients with HBeAg-Positive Chronic Hepati-tis B: A Five-Year Observational Cohort Study. Journal of Viral Hepatitis, 24, 12-20. https://doi.org/10.1111/jvh.12755
|
[10]
|
Liang, K.-H., Hsu, C.-W., Chang, M.-L., et al. (2016) Peginterferon Is Su-perior to Nucleos(t)ide Analogues for Prevention of Hepatocellular Carcinoma in Chronic Hepatitis B. The Journal of In-fectious Diseases, 213, 966-974.
https://doi.org/10.1093/infdis/jiv547
|
[11]
|
王贵强, 段钟平, 王福生, 等. 慢性乙型肝炎防治指南(2019年版) [J]. 实用肝脏病杂志, 2020, 23(1): 9-32.
|
[12]
|
Lim, S.G., Yang, W.L., Ngu, J.H., et al. (2022) Switching to or Add-on Peginterferon in Patients on Nucleos(t)ide Analogues for Chronic Hepatitis B: The SWAP RCT. Clinical Gastroenterol-ogy and Hepatology, 20, e228-e250.
https://doi.org/10.1016/j.cgh.2021.04.031
|
[13]
|
Cheng, J., Zhao, Q., Zhou, Y., et al. (2020) Interferon Alpha In-duces Multiple Cellular Proteins That Coordinately Suppress Hepadnaviral Covalently Closed Circular DNA Transcrip-tion. Journal of Virology, 94, e00442-20.
https://doi.org/10.1128/JVI.00442-20
|
[14]
|
Ren, P., Cao, Z., Mo, R., et al. (2018) Interferon-Based Treatment Is Superior to Nucleos(t)ide Analog in Reducing HBV-Related Hepatocellular Carcinoma for Chronic Hepatitis B Patients at High Risk. Expert Opinion on Biological Therapy, 18, 1085-1094. https://doi.org/10.1080/14712598.2018.1518423
|
[15]
|
中华人民共和国国家卫生健康委员会. 原发性肝癌诊疗指南(2022年版) [J]. 肿瘤综合治疗电子杂志, 2022, 8(2): 16-53.
|
[16]
|
Calderaro, J., Petitprez, F., Becht, E., et al. (2019) Intra-Tumoral Tertiary Lymphoid Structures Are Associated with a Low Risk of Early Recurrence of Hepatocel-lular Carcinoma. Journal of Hepatology, 70, 58-65.
https://doi.org/10.1016/j.jhep.2018.09.003
|
[17]
|
Zhou, H.-B., Li, Q.-M., Zhong, Z.-R., et al. (2015) Level of Hepa-titis B Surface Antigen Might Serve as a New Marker to Predict Hepatocellular Carcinoma Recurrence Following Cura-tive Resection in Patients with Low Viral Load. American Journal of Cancer Research, 5, 756-771.
|
[18]
|
Liu, W.-R., Tian, M.-X., Jin, L., et al. (2015) High Levels of Hepatitis B Surface Antigen Are Associated with Poorer Survival and Early Recurrence of Hepatocellular Carcinoma in Patients with Low Hepatitis B Viral Loads. Annals of Surgical Oncolo-gy, 22, 843-850. https://doi.org/10.1245/s10434-014-4043-5
|
[19]
|
Huang, G., Lau, W.Y., Zhou, W.-P., et al. (2014) Prediction of Hepatocellular Carcinoma Recurrence in Patients with Low Hepatitis B Virus DNA Levels and High Pre-operative Hepatitis B Surface Antigen Levels. JAMA Surgery, 149, 519-527. https://doi.org/10.1001/jamasurg.2013.4648
|
[20]
|
Yoo, S., Kim, J.Y., Lim, Y.-S., Han, S. and Choi, J. (2022) Im-pact of HBsAg Seroclearance on Late Recurrence of Hepatitis B Virus-Related Hepatocellular Carcinoma after Surgical Resection. Journal of Hepatology, 77, 939-946.
https://doi.org/10.1016/j.jhep.2022.05.014
|
[21]
|
Sun, H.-C., Tang, Z.-Y., Wang, L., et al. (2006) Postoperative In-terferon α Treatment Postponed Recurrence and Improved Overall Survival in Patients after Curative Resection of HBV-Related Hepatocellular Carcinoma: A Randomized Clinical Trial. Journal of Cancer Research and Clinical Oncol-ogy, 132, 458-465.
https://doi.org/10.1007/s00432-006-0091-y
|
[22]
|
赵家锋, 王建南, 吴青松, 等. 干扰素治疗原发性肝癌的临床疗效观察[J]. 实用临床医药杂志, 2011, 15(11): 133-134+139.
|
[23]
|
Lo, C.M., Liu, C.L., Chan, S.C., et al. (2007) A Randomized, Controlled Trial of Postoperative Adjuvant Interferon Therapy after Resection of Hepatocellular Carcinoma. Annals of Surgery, 245, 831-842.
https://doi.org/10.1097/01.sla.0000245829.00977.45
|
[24]
|
Chen, L.-T., Chen, M.-F., Li, L.-A., et al. (2012) Long-Term Results of a Randomized, Observation-Controlled, Phase III Trial of Adjuvant Interferon Alfa-2b in Hepato-cellular Carcinoma after Curative Resection. Annals of Surgery, 255, 8-17. https://doi.org/10.1097/SLA.0b013e3182363ff9
|
[25]
|
Qi, W., Zhang, Q., Xu, Y., et al. (20200) Peg-Interferon and Nucleos(t)ide Analogue Combination at Inception of Antiviral Therapy Improves Both Anti-HBV Efficacy and Long-Term Survival among HBV DNA-Positive Hepatocellular Carcinoma Patients after Hepatectomy/Ablation. Journal of Viral Hepatitis, 27, 387-396.
https://doi.org/10.1111/jvh.13236
|
[26]
|
Lin, S.-M., Lin, C.-J., Hsu, C.-W., et al. (2004) Prospective Randomized Controlled Study of Interferon-Alpha in Preventing Hepatocellular Carcinoma Recurrence after Medical Ablation Therapy for Primary Tumors. Cancer, 100, 376-382.
https://doi.org/10.1002/cncr.20004
|
[27]
|
Li, M., Lu, C., Cheng, J., et al. (2009) Combination Therapy with Transarterial Chemoembolization and Interferon-α Compared with Transarterial Chemoembolization Alone for Hepatitis B Virus Related Unresectable Hepatocellular Carcinoma. Journal of Gastroenterology and Hepatology, 24, 1437-1444.
https://doi.org/10.1111/j.1440-1746.2009.05863.x
|
[28]
|
肖华, 许若才, 刘寒春, 等. 射频消融联合索拉非尼和干扰素治疗复发性肝癌的临床研究[J]. 中国现代手术学杂志, 2015, 19(5): 338-342.
|
[29]
|
Hu, B., Yu, M., Ma, X., et al. (2022) IFNα Potentiates Anti-PD-1 Efficacy by Remodeling Glucose Metabolism in the Hepatocellular Carcinoma Microenvironment. Cancer Discovery, 12, 1718-1741.
https://doi.org/10.1158/2159-8290.CD-21-1022
|
[30]
|
Nagano, H., Obi, S., Hatano, E., et al. (2018) Multicenter, Randomized, Controlled Trial of S-1 Monotherapy versus S-1 and Interferon-α Combination Therapy for Hepatocellular Carcinoma with Extrahepatic Metastases. Hepatology Research, 48, 717-726. https://doi.org/10.1111/hepr.13067
|
[31]
|
Wonganan, O., He, Y.-J., Shen, X.-F., et al. (2017) 6-Hydroxy-3-O-Methyl-Kaempferol 6-O-Glucopyranoside Potentiates the Anti-Proliferative Effect of Interferon α/β by Promoting Activation of the JAK/STAT Signaling by Inhibiting SOCS3 in Hepatocellular Carcinoma Cells. Toxicology and Applied Pharmacology, 336, 31-39.
https://doi.org/10.1016/j.taap.2017.10.004
|
[32]
|
Igbe, I., Shen, X.-F., Jiao, W., et al. (2017) Dietary Quercetin Po-tentiates the Antiproliferative Effect of Interferon-α in Hepatocellular Carcinoma Cells through Activation of JAK/STAT Pathway Signaling by Inhibition of SHP2 Phosphatase. Oncotarget, 8, 113734-113748. https://doi.org/10.18632/oncotarget.22556
|